ArticleJournal of oral biology and craniofacial research
SND1, a novel m6A RNA regulator: Its high expression correlates with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A comparison of honeybee and scorpion venoms as anticancer agents against three different cancer cell lines: lung, colon, and breast cancer.Frontiers in toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The multifunctional protein SND1 (Staphylococcal Nuclease and Tudor Domain Containing 1) is involved in transcriptional control, RNA metabolism, and tumour development. While its role in several cancer types has been studied, little is known about its importance in head and neck squamous cell carcinoma (HNSCC). This study investigates the expression patterns, clinical relevance, and functional role of SND1 in HNSCC. Methods: SND1 expression in the TCGA-HNSCC dataset was examined using multiple databases, including TIMER, Protein Atlas, and UALCAN. Further SND1 expression was validated using real-time PCR. The prognostic impact of SND1 in HNSCC patients was analyzed using Kaplan-Meier survival analysis. Protein-protein interactions and pathway enrichment analyses were conducted to elucidate the SND1 functional role. Results: The expression of SND1 was significantly elevated in HNSCC tissues compared to normal tissues. Higher grade, metastasis, TP53 alterations, HPV status, and advanced tumour stage were all substantially associated with elevated SND1 expression. According to Kaplan-Meier analysis, a lower overall survival rate was linked to SND1 high expression. Analysis of protein interactions identified partners such as AGO2, FXR1, and STAT5, which connect SND1 to carcinogenic pathways including JAK-STAT signalling. Functional enrichment pathways indicated SND1 role in oncogene translation regulation and head and neck carcinoma. Conclusion: SND1 overexpression in HNSCC indicates a poor prognosis and unfavorable clinicopathological features. Due to its role in key cancer pathways, SND1 could serve as a useful biomarker for prognosis and a potential target for treatment. Improving patient outcomes requires further research into its molecular mechanisms and the development of treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.